The vaccine suspensions have provoked debate over whether it was prudent to put AstraZeneca inoculations on hold just as vaccination campaigns were beginning to gather pace.
The fresh suspensions were a major blow to a global immunisation campaign that experts hope will help end a pandemic that has already killed over 2.6 million people.
AstraZeneca says it found no evidence of increased risk of blood clot conditions after reviewing reported cases among over 17 million people who received its Covid-19 vaccine.